Drug profile · INN
rotigotine
NEUPRO
rotigotine (NEUPRO) is a d2-like dopamine receptor agonist. Route of administration: transdermal. Current US regulatory status: approved.
Drug details — rotigotine
- US status
- approved
- Class
- Nervous system (N04)
- Route
- TRANSDERMAL
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
rotigotine (NEUPRO) is a d2-like dopamine receptor agonist. Route of administration: transdermal. Current US regulatory status: approved.
Key facts
Mechanism of action
D2-like dopamine receptor agonist
Primary target: D2-like dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is rotigotine?
rotigotine (NEUPRO) is a d2-like dopamine receptor agonist. Route of administration: transdermal. Current US regulatory status: approved.
What is the brand name for rotigotine?
NEUPRO is a marketed brand name for rotigotine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rotigotine?
rotigotine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.